-
Biopharmaceutics & Drug Disposition 1984The purpose of the study was to examine the bioequivalence of five commercially available oral prednisone products. The in vivo study utilized 18 healthy males, each of... (Clinical Trial)
Clinical Trial Randomized Controlled Trial
The purpose of the study was to examine the bioequivalence of five commercially available oral prednisone products. The in vivo study utilized 18 healthy males, each of whom was administered 20 mg of prednisone as a reference solution or as a tablet in a 6-week, six-way crossover design. Blood was collected and serum was assayed, using an HPLC procedure specific for prednisone and prednisolone. Mean pharmacokinetic parameters (t 1/2, ke, Cmax, tmax, and AUC) were determined. ANOVA was performed on the prednisone and prednisolone data (F-test, p less than 0.05) as well as Duncan's multiple range analysis. Dissolution tests were also performed on each of the five products in order to test the relationship between dissolution and bioequivalence among prednisone products. The in vitro study consisted of a standard USP dissolution test which included tablets from the same lots as the tablets used in the in vivo study. The data showed no statistical difference in any of the pharmacokinetic parameters among tableted products, subjects, or dosing periods in the study. There was also no statistical difference in the dissolution study among the five commercial tablet forms.
Topics: Adolescent; Adult; Biological Availability; Chemistry, Pharmaceutical; Half-Life; Humans; Kinetics; Male; Prednisolone; Prednisone; Solubility; Tablets; Therapeutic Equivalency
PubMed: 6525441
DOI: 10.1002/bdd.2510050405 -
Water Science and Technology : a... Dec 2018This study evaluated the prednisone removal from aqueous solutions using adsorption by an activated carbon of vegetal origin (VAC). A central composite rotatable design...
This study evaluated the prednisone removal from aqueous solutions using adsorption by an activated carbon of vegetal origin (VAC). A central composite rotatable design (CCRD) and the response surface methodology (RSM) were used to verify the influence of the parameters: pH, adsorbent dose and prednisone concentration in a batch adsorption process. Among the analyzed parameters, only the adsorbent dose and the prednisone concentration were statistically significant (α = 0.05) and the critical values obtained were adsorbent dose: 1.87 g/L, pH 7.56 and prednisone concentration: 3.66 mg/L with 77.51% of prednisone removal by VAC. The kinetic study of the adsorption of prednisone reached the equilibrium in 4 h. The pseudo-first-order model described adequately the kinetics data behavior. The equilibrium experimental data obtained at different temperatures showed that the VAC has a maximum adsorption capacity of 18.04 mg/g at a temperature of 30 °C. The prednisone removal decreased by the increasing temperature and the Langmuir isotherm well described the experimental data (R² > 0.98). Thermodynamic results shown that the prednisone removal of aqueous solutions by VAC is spontaneous and favorable process.
Topics: Adsorption; Charcoal; Hydrogen-Ion Concentration; Kinetics; Prednisone; Solutions; Temperature; Thermodynamics; Water Pollutants, Chemical; Water Purification
PubMed: 30699084
DOI: 10.2166/wst.2018.515 -
Neurology Feb 2000Laboratory and epidemiologic studies suggest that anti-inflammatory/immunosuppressive therapy may be useful in the treatment of AD. In preliminary studies, a regimen of... (Clinical Trial)
Clinical Trial Randomized Controlled Trial
BACKGROUND
Laboratory and epidemiologic studies suggest that anti-inflammatory/immunosuppressive therapy may be useful in the treatment of AD. In preliminary studies, a regimen of low to moderate dose prednisone was found to suppress peripheral inflammatory markers without adverse effects in subjects with AD.
METHODS
We conducted a randomized, placebo-controlled multicenter trial to determine whether prednisone treatment slowed the rate of cognitive decline in AD. The active treatment regimen consisted of an initial dose of 20 mg of prednisone daily for 4 weeks tapered to a maintenance dose of 10 mg daily for 1 year, followed by gradual withdrawal during an additional 16 weeks. The primary outcome measure was the 1-year change in the cognitive subscale of the AD Assessment Scale.
RESULTS
A total of 138 subjects were randomized to the drug and placebo groups. There was no difference in cognitive decline between the prednisone and placebo treatment groups in the primary intent-to-treat analysis, or in a secondary analysis considering completers only. Subjects treated with prednisone showed behavioral decline compared with those in the placebo group.
CONCLUSION
A low-dose regimen of prednisone is not useful in the treatment of AD.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Male; Prednisone
PubMed: 10680787
DOI: 10.1212/wnl.54.3.588 -
Pediatrics Dec 1959
Topics: Leukemia; Prednisone
PubMed: 14405725
DOI: No ID Found -
Nederlands Tijdschrift Voor Geneeskunde 2012Physicians pride themselves on practicing evidence-based medicine. However, these principles appear not to apply in the case of glucocorticoid therapy for rheumatoid...
Physicians pride themselves on practicing evidence-based medicine. However, these principles appear not to apply in the case of glucocorticoid therapy for rheumatoid arthritis (RA). Despite a sizable body of evidence, glucocorticoids are underutilised in the treatment of RA. Hench's 1950 acceptance speech for the Nobel Prize (which he shared with Kendall and Reichstein for the discovery of glucocorticoids) illustrated his awareness of the benefits and risks of these agents. Although glucocorticoids have proved beneficial in randomized trials from 1955 onwards, only a perception of harm has endured. The recently published CAMERA-2 trial data could be the final piece of evidence added to the substantial body of literature proving that prednisone 10 mg/d given for 2 years in early RA, in addition to high-dose methotrexate, is better than methotrexate alone in inducing remission and preventing joint damage, and is accompanied by fewer side effects. Existing treatment guidelines need to be urgently updated to reflect these findings.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Evidence-Based Medicine; Glucocorticoids; Humans; Practice Guidelines as Topic; Prednisone; Treatment Outcome
PubMed: 22871244
DOI: No ID Found -
The Journal of Pediatrics Mar 1968
Topics: Face; Female; Head; Hemangioma, Cavernous; Humans; Infant; Male; Prednisone
PubMed: 5639749
DOI: 10.1016/s0022-3476(68)80208-2 -
Deutsches Medizinisches Journal Jun 1958
Topics: Humans; Prednisone
PubMed: 13547938
DOI: No ID Found -
British Medical Journal Mar 1973
Topics: Herpes Zoster; Humans; Neuralgia; Prednisone
PubMed: 4692724
DOI: 10.1136/bmj.1.5854.679-b -
Deutsche Medizinische Wochenschrift... Mar 1958
Topics: Addison Disease; Adrenal Insufficiency; Humans; Hypoadrenocorticism, Familial; Prednisone
PubMed: 13537673
DOI: 10.1055/s-0028-1114248 -
Journal of Pharmaceutical Sciences Oct 1975A three-way crossover bioavailability study was performed using nine adult male volunteers with three different commercial prednisone tablets. Plasma samples were... (Clinical Trial)
Clinical Trial
A three-way crossover bioavailability study was performed using nine adult male volunteers with three different commercial prednisone tablets. Plasma samples were assayed for prednisolone, the active metabolite of prednisone, by a radioimmunoassay method. Statistical analysis showed significant differences in the rate of appearance of prednisolone in plasma but not in the amount converted to prednisolone. The results suggest that differences in in vivo rates of appearance of prednisolone in plasma correlate with in vitro rates of dissolution.
Topics: Adult; Biological Availability; Clinical Trials as Topic; Dexamethasone; Drug Administration Schedule; Humans; Kinetics; Male; Prednisolone; Prednisone; Solubility; Tablets; Time Factors
PubMed: 1102660
DOI: 10.1002/jps.2600641035